Related Experiment Video
Updated: Dec 16, 2025

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
Published on: May 23, 2025
CRISPR, Patents, and the Public Health
1Innovation Center for Law and Technology, New York Law School, New York, NY; Health Policy and Management, Columbia University Mailman School of Public Health, New York, NY.
Abstract:
Patent issues surrounding CRISPR, the revolutionary genetic editing technology, may have important implications for the public health. Patents maintain high prices for novel therapies, limiting patient access. Relatedly, insurance coverage for expensive therapies is waning. Patents also misallocate research and development resources to profitable disease indications rather than those that necessarily impinge on the public health. And it is unclear how CRISPR therapies will figure into the current regulatory framework for biosimilars. Policy makers and physicians should consider these issues now, before CRISPR therapies become widely adopted-and entrenched-in the marketplace.
Related Concept Videos
CRISPR/Cas9 Genome Editing
The Antiviral System of Bacteria and Archaea: CRISPR
CRISPR
CRISPR and crRNAs
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...
What is Genetic Engineering?
Homologous Recombination

